Total Funding
53
42
Total FundingConvertible Note raised
Growth Score
-4 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
108871
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
Acquired by 
Maxwell Biomedical
- Jeff Peters: CEO and PresidentPast Role: Anulex Technologies, Chief Executive Officer
Brent Shelton: VP Development
About the Company
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition.
It was founded in 2008 and headquartered in Minneapolis, Minnesota.
